InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,018.39
(
-0.34%
)
US TECH 100
16,952.00
(
-0.19%
)
Dow Jones
37,903.29
(
0.23%
)
Brent Oil
83.69
(
0.17%
)
Bitcoin
57,307.62
(
-1.60%
)
Post# of 251670
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119535
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 211178

Thursday, 06/01/2017 10:35:50 AM

Thursday, June 01, 2017 10:35:50 AM

Post# of 251670
OCRX starts phase-2a trial for oral formulation of OCR-002 in cirrhotic patients—results expected by year-end:

https://finance.yahoo.com/news/ocera-initiates-phase-2a-study-130500660.html

The Phase 2a portion of the trial is an open-label, multiple-dose, randomized, 3-period crossover study. It is designed to evaluate the steady-state pharmacokinetics and pharmacodynamics of three times daily administration of three daily dose regimens, 6, 12 and 21 grams, of OCR-002 tablets in 18 patients with Child-Pugh B cirrhosis. We expect to complete the trial and report top-line results by the end of 2017.

Meanwhile, OCRX will meet with FDA on how to proceed with the IV formulation (#msg-131214002).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up